“2021 will be a transformative year for biopharma and the life sciences. It will be the year where the credibility and power of science applied to human health will shine.” These words from Usman “Oz” Azam, president and CEO of Tmunity Therapeutics Inc., encapsulate the feelings of many of those working in a sector that has delivered vaccines and therapeutics at unprecedented speed in response to a terrifying new infectious disease that swept around the world in a few short weeks.
Eight Themes That Will Shape Biopharma In Transformational 2021
A year after COVID-19 first turned the world upside down, executives across the biopharma industry consider what 2021 holds in store. The impact of the pandemic will have profound and long-lasting implications for a sector that has been at the heart of responding to the global health challenge.
More from Business Strategy
More from In Vivo
• By
Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.
• By
During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.
• By
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.